MedTrace Logo

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

NCT04594135 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-02

No results posted yet for this study

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.

Conditions

  • T-cell Acute Lymphoblastic Leukemia
  • T-cell Non-Hodgkin Lymphoma

Interventions

DRUG

anti-CD5 CAR T cells

anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells

Sponsors & Collaborators

  • iCAR Bio Therapeutics Ltd.

    collaborator INDUSTRY

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • iCell Gene Therapeutics

    lead INDUSTRY

Principal Investigators

  • Hongyu Zhang, MD/PhD · Peking University Shenzhen Hospital, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04594135 on ClinicalTrials.gov